SEC Form 4 research
| Issuer | Latigo Biotherapeutics, Inc. |
|---|---|
| Tickers | LTGO |
| Reporting owners | 28 |
| Officers and directors | 1 |
| Last public filing | 2026-08-11 |
| Available | Trade date | Reporting owners | Code | Shares | Price | Reported value |
|---|---|---|---|---|---|---|
| 2026-08-10 | 2026-08-10 | Tananbaum James B. | P | 140,000 | $18 | Not reported |
| 2026-08-10 | 2026-08-06 | SMITH TODD N | A | 105,542 | $0 | Not reported |
| 2026-08-10 | 2026-08-10 | Foresite Capital Fund V, L.P., Foresite Capital Fund VI LP, Foresite Capital Management V, LLC, Foresite Capital Management VI LLC, Foresite Capital Opportunity Fund V, L.P., Foresite Capital Opportunity Management V, LLC | P | 140,000 | $18 | Not reported |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.